aamc.org does not support this web browser. Learn more about the browsers we support.

New section

Content Background

New section

HRSA Proposed Rule Requires FQHC Patients Access to Insulin at 340B Price

September 25, 2020

New section

New section

CONTACTS
Mary Mullaney, Director, Hospital Payment Policies

The Health Resources and Services Administration (HRSA) released a proposed rule on Sept. 24 that would require Federally Qualified Health Centers (FQHCs) participating in the 340B Drug Pricing Program to provide low-income health center patients access to insulin and/or injectable epinephrine at no more than the 340B price. This follows Executive Order 13937, which President Trump signed in July [see Washington Highlights, July 28]. 

FQHCs enrolled in the 340B Program would be required to make 340B-acquired insulin and injectable epinephrine available to low-income health center patients. Low-income patients are defined as individuals or families with annual incomes at or below 350% of the Federal Poverty Guidelines. Patients enrolled in an insurance coverage with a high cost sharing for either drug, a high deductible, or are uninsured, would be charged no more than the 340B price to acquire the drug, plus a minimal administration fee. FQHCs would not be required to charge third party payers the discounted price.

Public comments are due October 28, 2020.

New section

New section